Skip to main content
Back to search

University of Missouri - Columbia

Time is running out for the MURR, as it has only 15 years remaining on its current operating license, which was most recently renewed in 2017. American global leadership in nuclear science, and medical isotope technology cannot continue without replacing at least some of the national research reactor assets. Because competing nations are already years ahead and the design, approval construction and commissioning of an expanded research reactor in Columbia will take at least a decade, it is imperative that this effort begin now. A radiopharmaceutical is a drug that consists of a medical radioisotope incorporated into a pharmaceutical molecule. The pharmaceutical molecule conveys the radioisotope to specifically targeted organs, tissues or cells and is used in a clinic or hospital to diagnose and treat disease. In recent years, medical research teams have started to unlock the huge potential of new drug compounds, for both diagnostic and therapeutic applications, and research reactor derived radiopharmaceuticals are now one of the most powerful tools in precision medicine. The now 55-year-old University of Missouri Research Reactor (MURR) is the sole domestic producer of a wide range and large number of medical isotopes and radiopharmaceuticals, which are delivered every week all over America to companies, clinics, and hospitals. Because the most important medical isotopes have half-lives of hours or days, they cannot be stockpiled and they need to be manufactured and distributed every week. Due to these short-half lives it also means relying on foreign production for such treatments would introduce unacceptable transportation and supply chain risks (including potential export restrictions by foreign governments) that could cause delays in patient diagnosis, and/or cancellation of scheduled cancer treatments at major hospitals and clinics all over the country.

Federal Funding Lifecycle

FY2023

FFID tracks stages 1–2 — stages 3–5 vary by agency, assistance type, and earmark structure.

Congressional Request

Member submits CPF / CDS

FFID

Enacted

Signed into appropriations law

FFID

Agency Administration

Procurement route not yet determined

SAM.gov / Grants.gov

Opportunity posted publicly

Federal Award

Obligation recorded in USASpending

Funding enacted — no verified award linked by FFID. The downstream procurement route — grant, cooperative agreement, or competitive solicitation — depends on the agency and earmark type. Check SAM.gov and Grants.gov for current status.

Evidence Dossier

1 source

Federal Award Record

Start a free trial to access this section.

Start free trial →

Supporting Evidence

Start a free trial to access this section.

Start free trial →

Tier A = Congressional Record or GovInfo. Tier B = committee report or member disclosure. ✓ Verified = exact document match. ~ Verified recipient = entity-level match only.

Enacted — no verified award linked by FFID

This project has been enacted into law. FFID has not yet linked a verified feder

Start a free trial to see the full commercial context →

Project Description

Time is running out for the MURR, as it has only 15 years remaining on its current operating license, which was most recently renewed in 2017. American global leadership in nuclear science, and medical isotope technology cannot continue without replacing at least some of the national research reactor assets. Because competing nations are already years ahead and the design, approval construction and commissioning of an expanded research reactor in Columbia will take at least a decade, it is imperative that this effort begin now. A radiopharmaceutical is a drug that consists of a medical radioisotope incorporated into a pharmaceutical molecule. The pharmaceutical molecule conveys the radioisotope to specifically targeted organs, tissues or cells and is used in a clinic or hospital to diagnose and treat disease. In recent years, medical research teams have started to unlock the huge potential of new drug compounds, for both diagnostic and therapeutic applications, and research reactor derived radiopharmaceuticals are now one of the most powerful tools in precision medicine. The now 55-year-old University of Missouri Research Reactor (MURR) is the sole domestic producer of a wide range and large number of medical isotopes and radiopharmaceuticals, which are delivered every week all over America to companies, clinics, and hospitals. Because the most important medical isotopes have half-lives of hours or days, they cannot be stockpiled and they need to be manufactured and distributed every week. Due to these short-half lives it also means relying on foreign production for such treatments would introduce unacceptable transportation and supply chain risks (including potential export restrictions by foreign governments) that could cause delays in patient diagnosis, and/or cancellation of scheduled cancer treatments at major hospitals and clinics all over the country.

Recipient Organization

University of Missouri - Columbia

Want to see more like this?

Start a free 7-day trial for full member intelligence, recipient funding history, opportunity scores, CSV export, and all 112,898 projects.

Start free trial

Data Provenance

Source
House Appropriations Committee
Status
enacted
Fiscal Year
FY2023
Category
other unclassified
Use Case
research innovation

Found an error in this record?

Report a data error
Technical & source detail
Record ID
05c4486e-87d1-4624-a907-e6dab96b7035

Embed this project

Share a live status card on your site or article.

<iframe src="https://federalfundingintelligence.com/api/embed/05c4486e-87d1-4624-a907-e6dab96b7035" width="100%" height="190" frameborder="0" style="border:none;border-radius:12px;" title="Federal earmark project"></iframe>

Procurement pursuit intelligence

This project has been enacted. FFID maps funded projects to likely downstream procurement channels — including recipient portals, state and local systems, agency programs, and Grants.gov. SAM.gov is monitored, but many CPF/CDS-funded opportunities appear first through recipient or state/local procurement systems.

Principals

BL

Blaine Luetkemeyer

R · MO · House

(202) 225-2956

Confirmed from FFID congressional source

UC

University of Missouri - Columbia

Grant recipient

Confirmed from FFID congressional source · website not yet enriched

FA

Federal agency

Administering agency

Inferred pathway based on agency

Inferred procurement pathway

low confidence

Likely procurement owner

unknown

Funding vehicle

grant

Expected channel

Multiple channels — see below

FFID could not determine the procurement channel with high confidence for this agency and category combination. Check the agency program page, Grants.gov, the state procurement portal, and the recipient's own procurement page.

Agency not specifically mapped. Check Grants.gov and the recipient's own procurement portal.

Discovery sources to check manually

Discovery only

These portals are not verified matches for this project. SAM.gov and state portals are general search starting points — not confirmed procurement channels.

Not project-specific. Portal coverage varies by state. Check all channels manually.

Procurement signals

Procurement monitoring has not yet run for this project. No conclusion can be drawn about whether an opportunity exists.